Verona Pharma plc

    Verona Pharma plc

    NNASDAQ:VRNA
    - -
    USD
    - -
    - -
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    0.68
    0.01
    - -
    0.52
    2.65
    Basic EPS, GAAP
    -0.11
    -0.1
    -0.04
    -0.09
    -0.03
    -2.53
    -1.92
    -3.08
    -1.98
    -0.94
    -1.04
    -0.69
    -2.13
    -0.97
    Free Cash Flow per Basic Share
    -0.11
    -0.08
    -0.05
    -0.08
    -0.03
    -2.58
    -1.77
    -3.28
    -1.37
    -0.56
    -0.91
    -0.63
    -1.51
    -0.88
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -0.43
    -0.49
    -0.21
    -0.27
    -0.15
    -5.42
    -6.12
    -10.22
    -5.33
    -3.92
    -4.42
    -4.36
    -6.35
    -6.23
    Tangible Book Value per Share
    0.04
    0.02
    0.15
    0.04
    0.19
    9.55
    5.83
    3.2
    5.61
    2.49
    3.48
    3.14
    2.5
    3.32
    Basic Weighted Avg Shares
    38
    43
    108
    126
    209
    11
    13
    13
    33
    59
    66
    79
    82
    84
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    40
    - -
    - -
    42
    222
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -144.21
    -14,435.81
    - -
    -357.22
    -24.29
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    1
    1
    1
    1
    1
    Net Income, GAAP
    -4
    -4
    -4
    -11
    -6
    -28
    -25
    -41
    -65
    -56
    -69
    -54
    -173
    -81
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -138.92
    -15,000.22
    - -
    -410.18
    -36.62
    Working Capital
    2
    1
    17
    6
    41
    106
    78
    41
    188
    137
    224
    281
    411
    498
    LT Debt
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    5
    5
    10
    50
    122
    243
    Total Equity
    4
    3
    20
    8
    43
    108
    80
    43
    185
    148
    230
    249
    205
    278
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'24
    Mar'25
    Jun'25
    ST Debt
    1
    1
    1
    LT Borrowings
    120
    242
    242
    LT Finance Leases
    1
    1
    1
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    677
    681
    688
    Market Capitalization
    3,026
    4,059
    5,768

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'24
    Mar'25
    Jun'25
    Total Current Assets
    454
    501
    549
    Cash, Cash Equivalents & STI
    400
    401
    438
    Accounts Receivable, Net
    31
    62
    83
    Inventories
    6
    7
    9
    Total Current Liabilities
    43
    57
    51
    Payables & Accruals
    38
    55
    50
    ST Debt
    1
    1
    1
    Deferred Revenue
    1
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    80.93%
    71.7%
    -17.94%
    Free Cash Flow
    59.3%
    37.3%
    144.48%
    Net Income, GAAP
    78.11%
    53.53%
    218.96%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    6
    37
    42
    2025
    76
    103
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.22
    -0.11
    -0.18
    - -
    -0.69
    2024
    -0.32
    -0.87
    -0.53
    -0.41
    -2.13
    2025
    -0.19
    0.14
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • gurufocus.com

      Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio

    • gurufocus.com

      Mueller Industries Inc: A Key Focus in Mario Gabelli's Latest 13F Filing

    • gurufocus.com

      Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio

    • defenseworld.net

      Sumitomo Mitsui Trust Group Inc. Buys 205 Shares of Verona Pharma PLC American Depositary Share $VRNA

    • defenseworld.net

      Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on Monday

    • globenewswire.com

      Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

    • globenewswire.com

      Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

    • globenewswire.com

      Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

    • zacks.com

      All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy

    • fool.com

      Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today

    • zacks.com

      Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks

    • zacks.com

      Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now

    • zacks.com

      What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?

    • globenewswire.com

      $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)

    • businesswire.com

      VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

    • zacks.com

      Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

    • reuters.com

      Major deals involving U.S. drugmakers and biotechs over the past decade

    • youtube.com

      Merck to Buy Verona Pharma for Around $10 Billion

    • businesswire.com

      VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders

    • zacks.com

      Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck